Professors Comanor and Scherer File Comments with FTC Criticizing Approval of Pfizer-Wyeth and Merck-Schering Mergers

Nov 17 2009
Testimony and Interventions

The two former Directors of the FTC's Bureau of Economics, now at UCLA and Harvard, suggest the agency's treatment of innovation markets is too narrow, underestimating the two mergers' likely effects on the rate of innovation in the pharmaceutical industry.